President Donald Trump has unveiled a groundbreaking deal with Pfizer, promising steep discounts on medications for Medicaid patients. This move aims to tackle the long-standing issue of skyrocketing drug prices in the U.S.
According to NBC News, Trump announced the agreement on Tuesday, highlighting a new federal website called "TrumpRx" that will direct consumers to Pfizer’s discounted drugs. The deal also grants Pfizer a three-year reprieve from planned tariffs on foreign-made pharmaceuticals, set to begin Wednesday.
Under this arrangement, a wide range of Pfizer’s primary care and specialty brand-name drugs will see price cuts averaging 50%, with some discounts reaching as high as 85%. Specific examples include the menopause drug Duavee dropping to $30 and the overactive bladder drug Tobias falling to $42, both reflecting an 85% reduction.
The Trump administration hopes to roll out the TrumpRx website by early 2026, though it won’t directly sell medications. Instead, it will guide Americans, not just Medicaid patients, to manufacturers’ direct-to-consumer platforms.
Pfizer’s skin ointment Eucrisa, for instance, will be reduced by 80% to $162, showcasing the depth of these price slashes. Trump also declared that all new Pfizer drugs entering the U.S. market will adhere to these lowered rates.
Direct-to-consumer sales are rare in the pharmaceutical world, though companies like Novo Nordisk and Eli Lilly have recently ventured into similar models. The catch, however, is whether insurance will be accepted on TrumpRx, a detail officials have yet to clarify.
This agreement stems from Trump’s broader push for a “most favored nation” pricing model, initiated by an executive order in May. The policy seeks to align U.S. drug costs with the lowest prices paid in other wealthy nations.
Pfizer became the first drugmaker to sign on, with pricing negotiations based on net costs after rebates, reflecting what patients and insurers actually pay. The company also pledged a $70 billion investment in research, development, and domestic manufacturing as part of the deal.
Trump, speaking from the White House, called this a “really big announcement,” insisting it was something many deemed impossible. He hinted at future agreements with other drugmakers, though no specific names were mentioned.
Not everyone is sold on the deal’s effectiveness, with experts raising doubts about its scope and benefits. Drew Altman, CEO of KFF, noted it applies only to “one company and one program,” limiting its reach.
Stacie Dusetzina, a health policy professor at Vanderbilt University, argued that direct-to-consumer sales won’t help most Americans lower costs since they often require out-of-pocket payments. She called the announcement more of a “gimmick” that aids only a small fraction of people.
Dusetzina also warned that broader administration policies, like a 100% tariff on drugs, could ultimately raise prices for consumers. This, she suggested, might counteract any savings from the Pfizer deal.
Prescription drug costs in the U.S. remain notoriously higher than in other wealthy countries, even for generics, with drug spending comprising 10% of national health care costs. A 2022 KFF survey found that three in four Americans consider medication prices unaffordable.
Lawrence Gostin of Georgetown University questioned why Trump isn’t leveraging existing Medicare drug pricing negotiations, already authorized by Congress, instead of unilateral actions. His pointed query, “Why would the president act alone when he has an effective tool to lower prices?” cuts to the heart of the debate.
With significant cuts to Medicaid under this administration, the Pfizer deal’s focus on that program raises further questions about its timing and true intent. While the promise of lower costs is welcome, the path to meaningful reform remains murky, and Americans are right to demand clarity on whether this is a genuine step forward or a polished distraction.
